Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654314 · ClinicalTrials.gov registry record · Phase 3
Prevention of Delirium in Inpatients Utilizing Melatonin
A Phase 3 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 277
- Enrollment target
NCT02654314 is a Phase 3 study that was terminated before completion, run by Yale University. The registered enrollment target is 277 participants.
The verdict
NCT02654314, a Phase 3 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 277 participants
- Enrollment target
Study Summary
A double blind randomized controlled trial investigating melatonin, 5mg, compared to placebo, given to patients at least 65 years old, admitted to the hospital on a general medical floor, to prevent delirium.
Interventions
- OTHER Placebo
- DRUG Melatonin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-11-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02654314
The ClinicalTrials.gov registry entry for NCT02654314 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02654314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02654314 about?
NCT02654314 is a clinical study titled "Prevention of Delirium in Inpatients Utilizing Melatonin". A double blind randomized controlled trial investigating melatonin, 5mg, compared to placebo, given to patients at least 65 years old, admitted to the hospital on a general medical floor, to prevent delirium.
What is the current status of trial NCT02654314?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 277 participants. The study started on 2016-07. Estimated completion is 2017-11-03.
What interventions are being tested in trial NCT02654314?
The interventions under investigation include: Placebo (OTHER), Melatonin (DRUG).
Who is sponsoring clinical trial NCT02654314?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.